EMA Withdrawn: Rasilez HCT (aliskiren;hydrochlorothiazide) — Noden Pharma DAC

View source ↗

Summary

The EMA has withdrawn Rasilez HCT (aliskiren; hydrochlorothiazide) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Rasilez HCT (aliskiren; hydrochlorothiazide)

Snippet

Status: Withdrawn. Therapeutic area: Hypertension. MAH: Noden Pharma DAC. Decision date: 20/12/2021